Kidney Cancer Coverage from Every Angle

Brian I. Rini, MD, on Clinical Implications of Treatment With Pembrolizumab Plus Axitinib for RCC

Posted: Tuesday, June 15, 2021

Brian I. Rini, MD, of Vanderbilt University, discusses why the KEYNOTE-426 trial provides key evidence for clinicians giving first-line treatment to patients with renal cell carcinoma, whether or when sunitinib monotherapy can be beneficial, and some clinical pearls on managing side effects of pembrolizumab and axitinib combination therapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.